The Future of Pneumococcal Disease Prevention
This article, published in Vaccine, reviews the most recently developed pneumococcal conjugate vaccines (PCVs) that are now approved for use in children, a 10-valent vaccine and a 13-valent vaccine, as well as other new PCVs in development. In view of the 93 pneumococcal serotypes that are currently known, the authors conclude that additional vaccines with greater coverage, likely based on proteins common to all serotypes, will be needed in the future. ABSTRACT ONLY. (Learn how users in developing countries can gain free access to journal articles.)
Author(s): Rodgers GL, Klugman KP
Visit web page (English)
(Located at www.sciencedirect.com)
Citation: Rodgers GL, Klugman KP. The Future of Pneumococcal Disease Prevention. Vaccine. 2011;29(Supplement 3):C43-C48.